CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.21, no.11, 2021 (SCI-Expanded)
Article / Article
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
DLBCL, Prognosis, Survival, PET, Therapy, POSITRON-EMISSION-TOMOGRAPHY, CLINICAL-PRACTICE GUIDELINES, FDG-PET, RISK STRATIFICATION, RESPONSE ASSESSMENT, PROGNOSTIC VALUE, CT, PREDICTION, DIAGNOSIS, CRITERIA
Kocaeli University Affiliated:
Diffuse large B cell lymphoma is an aggressive lymphoma which fails to cure in first line almost in one third of patients. Earlier risk assessment and tailoring therapy with interim PET will select a group of patients having high risk to relapse. Although interim PET guided therapy has been established in Hodgkin Lymphoma; the role of interim PET in non-Hodgkin lymphomas is debated. In this study we searched the association of interim PET on survival in 103 DLBCL patients.Interim PET assessed by 5-point Deauville Score predicts PFS and OS with a PPV of 65.4% and a NPV of 77.9%.